Asieris Pharmaceuticals

Asieris Pharmaceuticals

CA - Palo Alto
Pharmaceutical1 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Small Molecules, Drug-Device Comvo Product

Error: Unreachable/Blocked

OncologyImmunology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

APL-1202 and APL-1501
Bladder Cancer
Phase 1
Clinical Trials (1)
NCT06034015A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT06435039A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT05743010A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis
Phase 1
APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2
Bladder Cancer
Phase 1
Clinical Trials (1)
NCT04601766A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets
Phase 1
Phase 1/2
Clinical Trials (1)
NCT06787950Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT03672240Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment
Phase 1/2
APL-1202 in combination with tislelizumab
Muscle Invasive Bladder Cancer
Phase 1/2
Clinical Trials (1)
NCT04813107A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer
Phase 1/2
Phase 2
Clinical Trials (1)
NCT04498702Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy
Phase 2
Hexaminolevulinate Hydrochloride
Bladder Cancer
Phase 3
Clinical Trials (1)
NCT05600322Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer
Phase 3
Phase 3
Clinical Trials (1)
NCT04484415Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)
Phase 3
APL-1202 in combination with Epirubicin
Non-muscle Invasive Bladder Cancer
Phase 3
Clinical Trials (1)
NCT04490993Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients
Phase 3
Phase 3
Clinical Trials (1)
NCT04736394A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2011
Portfolio: 12 clinical trials
H-1B (2023): 1 approval

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub